 |
Home | ||||||||
|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||
|
|
Our Faculty | ||||||||
|
|
|||||||||
|
|
Education | ||||||||
|
|
|||||||||
|
|
Patient Care | ||||||||
|
|
|||||||||
|
|
Research | ||||||||
|
|||||||||
|
|
|||||||||
|
|
Philanthropy/ Volunteering |
||||||||
|
|
|||||||||
|
|
Contact Us | ||||||||
Drug Development/Delivery/Analysis
Sherif Farag, M.D., Ph.D.
Bryan Schneider, M.D.
John Turchi, Ph.D.
Investigators involved in drug development are targeting novel pathways and cellular processes critical for tumor formation and progression.
Faculty:
Asok Antony, M.D.Sherif Farag, M.D., Ph.D.
Bryan Schneider, M.D.
John Turchi, Ph.D.
Investigators involved in drug development are targeting novel pathways and cellular processes critical for tumor formation and progression.
Active Research Awards:
| Principal Investigator | Funding Agency | Project Title |
| Robert Hickey | U.S. Army | Development of a Breast Cancer Selective therapeutic Agent |
| Kathy Miller | The Breast Cancer Research Foundation | Genomic and Proteomic Analysis of Docetaxel and Capecitabine as Primary Chemotherapy for Stage II-III Breast Cancer |
| Kathy Miller | Susan G. Komen Breast Cancer Foundation | EphA2, a novel target for breast cancer therapy |
| George Sledge Jr. | The Breast Cancer Research Foundation | Therapeutic Targeting of Breast Cancer |
| Attaya Suvannasankha | Multiple Myeloma Research Foundation | From laboratory to clinic: Dimethylaminoparthenolide (DMAPT) in myeloma |
| John Turchi | Flight Attendant Medical Research Institute | Analysis of DNA repair capacity to predict and target chemoresistant small cell lung cancer |
| John Turchi | NIH – National Cancer Institute | Recognition and Repair of Cisplatin-DNA Damage |
